drugset

drugset / Trial / NCT03204929

Dose Escalation Study of Cu(II)ATSM in Parkinson's Disease

NCT03204929 ↗

Phase 1 Completed 31 enrolled Collaborative Medicinal Development Pty Limited

NaSingle-groupOpen-labelTreatment

Summary

Multicenter, open-label dose-escalation study

Timeline

Start: 2017-08-14
Primary completion: 2019-11-30
Completion: 2020-02-29

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ATSM COPPER (II)	Small molecule	12 mg	Oral

Indications